Literature DB >> 15776818

Formulation studies and in vivo evaluation of a flurbiprofen-hydroxypropyl beta-cyclodextrin system.

Ramprakash Govindarajan1, Mangal S Nagarsenker.   

Abstract

The purpose of this study was 1) to investigate in vivo advantages of a flurbiprofen (FPN)-hydroxypropyl beta-cyclodextrin (HPbetaCD) solid dispersion (SD) in rats, 2) to study factors affecting the drug release from SD formulations, and 3) to evaluate the pharmacokinetic profile of the drug when administered as SD, in humans. The solubility of FPN in water and dissolution media was evaluated as a function of HPbetaCD concentration. The SD was prepared by coevaporation from dilute aqueous NH3 and evaluated in rats. The release of the drug from tablet formulations and capsules of SD was studied in simulated gastric fluid and phosphate buffer, pH 7.2. The bioavailability of drug when administered as SD was evaluated in humans. HPbetaCD enhanced the solubility of the drug, and SD improved bioavailability and reduced ulcerogenicity of the drug in rats. The type of excipient used affected drug release from tablets. Presence of microcrystalline cellulose, a hydrophilic polymeric excipient, resulted in uptake of water and stabilization of the resulting gels-like structure of HPbetaCD-containing tablets. This adversely affected drug release. The release from capsules filled with SD was comparable to that obtained from plain SD powder. The drug-HPbetaCD association constant in water was much lower than the values reported in literature. The bioavailability (which could suffer in case of higher association constant) was enhanced on administration of SD-filled capsules to humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776818     DOI: 10.1081/pdt-49687

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  3 in total

1.  In Vitro and In Vivo Characterization of Drug Nanoparticles Prepared Using PureNano™ Continuous Crystallizer to Improve the Bioavailability of Poorly Water Soluble Drugs.

Authors:  Kohei Tahara; Masahiro Nishikawa; Ko Matsui; Koji Hisazumi; Risako Onodera; Yuichi Tozuka; Hirofumi Takeuchi
Journal:  Pharm Res       Date:  2016-06-14       Impact factor: 4.200

2.  Intravenous formulation of N-hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for inhibition of rat brain 20-hydroxyeicosatetraenoic acid formation.

Authors:  Ying Mu; Megan M Klamerus; Tricia M Miller; Lisa C Rohan; Steven H Graham; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

3.  In vivo bioavailability and therapeutic assessment of host-guest inclusion phenomena for the hydrophobic molecule etodolac: pharmacodynamic and pharmacokinetic evaluation.

Authors:  Vivek Ranjan Sinha; Honey Goel
Journal:  Sci Pharm       Date:  2010-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.